TScan Therapeutics, Inc. (TCRX) Stock Price, Financials & Summary | drillr

Skip to content

Sign in Sign up

Price chart

Aug 6Aug 11Aug 14Aug 19Aug 24Aug 27Sep 1Sep 4

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.2x

Market Cap

$26.54M

MomentumView details →

1D Return

+5.55%

YTD Return

−61.09%

RSI (14)

19.9

ValuationView details →

P/E (Fwd)

—

EV/EBITDA

−0.2x

Market Cap

$26.54M

RSI (14)

19.9

MomentumView details →

1D Return

+5.55%

YTD Return

−61.09%

SummaryUpdated Jun 1, 2026

TScan Therapeutics, Inc. (NASDAQ:TCRX) is a preclinical-stage biopharmaceutical company founded in 2018 and headquartered in Waltham, Massachusetts. The company went public in July 2021 and focuses on developing innovative T cell receptor-engineered T cell therapies for cancer treatment. TScan operates in the emerging field of cellular immunotherapy, specifically targeting both blood cancers and solid tumors through its proprietary T cell engineering platform.

Ask drillr about TScan Therapeutics, Inc. →

ProfitabilityView details →

Gross Margin

90.25%

Net Margin

−1655.35%

EBITDA Margin

−1575.60%

ROE (TTM)

−170.55%

ROA (TTM)

−68.66%

Asset Turnover

0.04x

GrowthView details →

Revenue YoY

+2.15%

EPS YoY

+16.51%

FCF YoY

+9.76%

Revenue CAGR 3Y

−8.63%

EPS CAGR 3Y

+12.28%

EBITDA YoY

+14.18%

EarningsView details →

EPS (Actual)

−$0.23

EPS Surprise

9.23%

Beats (12Q)

8/12

Next Q EPS Est

−$0.28

Avg Surprise (4Q)

15.64%

Rev Surprise

−43.95%

Capital & dividendView details →

Debt/Equity

1.32x

Current Ratio

3.37x

Quick Ratio

3.37x

Div Yield

—

Div Rate

—

Div Growth 1Y

—

Financials snapshotView financials →

Revenue (TTM)

7.11M

Net Income (TTM)

−117.71M

Op. CF (TTM)

−116.28M

Next earningsNov 11, 2026 →

Latest newsMore news →

TScan Therapeutics terminated CFO Jason A. Amello and CMO Chrystal Louis, effective September 2, 2026, and CEO Gavin MacBeath assumed the additional role of Chief Financial Officer.3d ago

TScan Therapeutics announced a strategic reorganization to focus on in vivo cell therapy for solid tumors, including a workforce reduction of approximately 75%, and paused further enrollment in the Phase 3 ALLOHA-2 study of TSC-101 due to insufficient capital, extending its runway into Q4 2027.3d ago

Similar companies

Plus Therapeutics, Inc.PSTV Evaxion Biotech A/SEVAX ABVC BioPharma, Inc.ABVC Tvardi Therapeutics, Inc.TVRD BeyondSpring Inc.BYSI Atossa Therapeutics, Inc.ATOS Find similar companies →

Latest newsMore news →

TScan Therapeutics terminated CFO Jason A. Amello and CMO Chrystal Louis, effective September 2, 2026, and CEO Gavin MacBeath assumed the additional role of Chief Financial Officer.3d ago TScan Therapeutics announced a strategic reorganization to focus on in vivo cell therapy for solid tumors, including a workforce reduction of approximately 75%, and paused further enrollment in the Phase 3 ALLOHA-2 study of TSC-101 due to insufficient capital, extending its runway into Q4 2027.3d ago TScan Therapeutics shared positive initial data from Cohort C of its Phase 1 ALLOHA study, validating its internal commercial-ready manufacturing process.24d ago